Product Licensing Deals In India Paying Off?
India has seen an uptick in in-licensing deals, with robust growth in the number of novel drugs in such arrangements delivering gains for both the domestic partner and innovator company.
You may also be interested in...
Oxford Biomedica is teaming with Santen to develop a gene therapy for an undisclosed eye disease. Shionogi inks a pair of partnerships for Chinese rights to lusutrombopag and epertinib.
Novartis’ Entresto has had a strong run in India, with two second brands in tow, while itraconazole and azilsartan therapies are among the other recent introductions that have gained traction in a competitive market.
Yesteryear rivals Roche and Cipla have sewn up a partnership under which Cipla will market a second brand of the Swiss giant’s Avastin (bevacizumab) and the